Steris | STE - Cash And Equivalent


Steris reported $482.3M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
3M USD 2.96B 774M Jun/2026
Accuray USD 41.29M 22.05M Dec/2025
Baxter International USD 2.15B 133M Jun/2026
Becton, Dickinson and Co. USD 708M 105M Jun/2026
Boston Scientific USD 539M 914M Jun/2026
CONMED USD 35.03M 5.79M Mar/2026
Cooper Companies USD 124.9M 14.3M Dec/2025
Dexcom USD 1.1B 13.2M Jun/2026
Ecolab USD 5.14B 4.62B Jun/2026
Edwards Lifesciences USD 2.9B 500M Jun/2026
Fortive USD 374.2M 18.1M Jun/2026
Getinge SEK 2.05B 909M Jun/2026
Globus Medical USD 507.74M 53.2M Jun/2026
Haemonetics USD 223.38M 22.06M Jun/2026
Idexx Laboratories USD 196.93M 3.6M Jun/2026
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 534.9M 54.5M Jun/2026
Integra LifeSciences USD 214.42M 22.39M Jun/2026
Intuitive Surgical USD 8.63B 646.3M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Olympus JPY 147.24B 93.98B Sep/2025
Orthofix International USD 103.81M 16.47M Jun/2026
Owens Minor USD 7.65M 329.23M Jun/2026
ResMed USD 1.47B 191.28M Jun/2026
Steris USD 482.3M 42.7M Jun/2026
Stryker USD 3.39B 513M Jun/2026
Tandem Diabetes Care USD 62.82M 116.51M Jun/2026
Teleflex USD 300.16M 9.25M Jun/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Zimmer Biomet Holdings USD 410M 14.2M Jun/2026